Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): An open-label, 2×2 factorial randomised phase 3 trial

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 201-212

  Earl, Helena M ^a,b,c,d   Vallier, Anne Laure ^c,d   Hiller, Louise ^e   Fenwick, Nicola ^f   Young, Jennie ^f   Iddawela, Mahesh ^g   Abraham, Jean ^b,c,d,h   Hughes Davies, Luke ^c,d   Gounaris, Ioannis ^h   McAdam, Karen ^d,i   Houston, Stephen ^j   Hickish, Tamas ^k   Skene, Anthony ^k   Chan, Stephen ^l   Dean, Susan ^m   Ritchie, Diana ⁿ   Laing, Robert ^j   Harries, Mark ^o   Gallagher, Christopher ^p   Wishart, Gordon ^d   Dunn, Janet ^e   Provenzano, Elena ^b,c,d   Caldas, Carlos ^a,b,c,d,h   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre ^*  (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

ⁱ PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^j ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^k ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^l NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^m POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁿ BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^o GUY S HOSPITAL   (United Kingdom)

^p ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; GEMCITABINE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RISK; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; UNITED KINGDOM; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84892987414     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70554-0     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 version 1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 2010, International Agency for Research on Cancer, Lyon, France.
2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012, 379:432-444. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
4. Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 1996, 14:35-45. The International Collaborative Cancer Group.
5. Levine MN, Bramwell VH, Pritchard KI, et al. Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil compared with cyclophosphamide, methotrexate and fluorouracil in pre-menopausal women with node-positive breast cancer. J Clin Oncol 1998, 16:2651-2658.
6. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 1996, 355:1851-1862.
7. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
8. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696.
9. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006, 24:5664-5671.
10. Earl HM Reporting of adjuvant breast cancer trials-when is the right time?. J Clin Oncol 2012, 30:1-2.
11. Poole CJ, Hiller L, Howard HC, et al. tAnGo: a randomised phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC). Proc Am Soc Clin Oncol 2008, abstr 506.
12. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005, 23:1401-1408.
13. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26:3950-3957.
14. Swain SM, Tang G, Geyer CE, et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 2013, 31:3197-3204. for National Surgical Adjuvant Breast and Bowel Project (NSABP).
15. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
16. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012, 30:11-18.
17. Provenzano E, Vallier A-L, Walland K, et al. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the Neo-tAnGo trial. Br J Cancer 2013, 108:866-872.
18. Earl HM, Hiller L, Dunn JA, et al. NEAT: National Epirubicin Adjuvant Trial-toxicity, delivered dose intensity and quality of life. Br J Cancer 2008, 99:1226-1231.
19. Alvarez RH, Bianchini G, Hsu L, et al. Clinical outcome of two sequences of administering paclitaxel (p) and anthracyclines (a) as primary systemic therapy (pst) and adjuvant chemotherapy (act) in breast cancer (bc) patients: a retrospective analysis from the MD Anderson Cancer Center (MDACC). Cancer Res 2010, 70:384. abstr P5-10-02.
20. Puhalla S, Mrozek E, Young D, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol 2008, 26:1691-1697.
21. Wildiers H, Dirix L, Neven P, et al. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 2009, 114:103-112.
22. Abe H, Mori T, Kawai Y, et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. Int J Clin Oncol 2013, 18:487-491.
23. Thiery-Vuillemin A, Llombart-Cussac A, Chaigneau L, et al. Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact. Breast 2011, 20:46-49.
24. Stearns V, Singh B, Tsangaris T, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003, 9:124-133.
25. Miller KD, Soule SE, Calley C, et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005, 89:187-197.
26. Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005, 23:1951-1961.
27. Polyzos A, Malamos N, Boukovinas I, et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 2010, 119:95-104.
28. Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011, 12:527-539. for EORTC 10944/BIG 1-00 study investigators.
29. Guo B, Villeneuve DJ, Hembruff SL, et al. Cross-resistance studies of isogenic drug-resistant breast tumour cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004, 85:31-51.
30. Pachmann K, Camaro O, Pacmann UA Influence of primary tumour chemotherapy in breast cancer on circulating tumour cells. Indications for massive cell release into circulation concurrent with tumour size. Breast Cancer Res Treat 2004, 88(suppl):S224.
31. Shi P, Wang MM, Jiang LY, et al. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression. Chin Med J (Engl) 2008, 121:1975-1979.
32. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009, 27:5685-5692.
33. Earl HM, Blenkinsop C, Grybowicz L, et al. ARTemis-randomised trial with neo-adjuvant chemotherapy for patients with early breast cancer. 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 4-8, 2012: abstr OT3-3-09.
34. von Minckwitz GM, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic subtypes. J Clin Oncol 2012, 30:1796-1804.
35. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer-highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747.
36. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309. for GBG and AGOBSG.
37. Buzdar A, Suman V, Meric-Bernstam F, et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. Proc Am Soc Clin Oncol 2013, 31. abstr 502.
38. Cortazar P, Zhang L, Untch M, et al. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). San Antonio Breast Cancer Symposium 2012. Cancer Res 2012, 72(suppl):S1-11.
39. Prowell TM, Pazdur R Perspective: pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012, 366:2438-2441.